AR082245A1 - Composicion farmaceutica de combinacion para tratar enfermedades funcionales o condiciones de tracto gastrointestinal - Google Patents
Composicion farmaceutica de combinacion para tratar enfermedades funcionales o condiciones de tracto gastrointestinalInfo
- Publication number
- AR082245A1 AR082245A1 ARP110102575A ARP110102575A AR082245A1 AR 082245 A1 AR082245 A1 AR 082245A1 AR P110102575 A ARP110102575 A AR P110102575A AR P110102575 A ARP110102575 A AR P110102575A AR 082245 A1 AR082245 A1 AR 082245A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- activated form
- enhanced activated
- pharmaceutical composition
- enhanced
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 6
- 239000000243 solution Substances 0.000 abstract 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 3
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 3
- 229960001340 histamine Drugs 0.000 abstract 3
- 239000012895 dilution Substances 0.000 abstract 2
- 238000010790 dilution Methods 0.000 abstract 2
- 230000001632 homeopathic effect Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000013674 S-100 Human genes 0.000 abstract 1
- 108700021018 S100 Proteins 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Composición farmacéutica de combinación que comprende: a) una forma activada potenciada de un anticuerpo a una Proteína S-100, b) una forma activada potenciada de un anticuerpo a histamina, y c) una forma activada potenciada de un anticuerpo a TNF-a. Se proporcionan varias materializaciones y variantes.Reivindicación 3: La composición farmacéutica de combinación de la reivindicación 2, caracterizada porque está en forma de tableta. Reivindicación 10: La composición farmacéutica de combinación de la reivindicación 1, caracterizada porque la forma activada potenciada de un anticuerpo a histamina es un anticuerpo monoclonal, policlonal o natural. Reivindicación 12: La composición farmacéutica de combinación de la reivindicación 1, caracterizada porque la forma activada potenciada de un anticuerpo a Proteína S-100 es un anticuerpo monoclonal, policlonal o natural. Reivindicación 14: La composición farmacéutica de combinación de la reivindicación 1, caracterizada porque la forma activada potenciada de un anticuerpo a TNF-a es un anticuerpo monoclonal, policlonal o natural. Reivindicación 22: Una composición farmacéutica para utilizarse en el tratamiento de un paciente que sufre de una enfermedad o condición de etiología funcional del tracto gastrointestinal, caracterizada porque dicha composición se obtiene mediante la provisión de a) una forma activada potenciada de un anticuerpo a histamina, b) una forma activada potenciada de un anticuerpo a Proteína S-100 y c) una forma activada potenciada de un anticuerpo a TNF-a, cada una preparada por dilución consecutiva repetida y agitación múltiple de cada solución obtenida conforme a la tecnología homeopática, y luego o bien combinando las soluciones potenciadas mediante mezcla, o bien, alternativamente, impregnando una masa de portador con dicha solución combinada o con las soluciones separadamente. Reivindicación 27: La composición farmacéutica de la reivindicación 22, caracterizada porque cada una de dichas formas activadas potenciadas de anticuerpo es una mezcla de diluciones homeopáticas C12, C30, y C200.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010129293/15A RU2500427C2 (ru) | 2010-07-15 | 2010-07-15 | Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта |
| RU2011124809/15A RU2532323C2 (ru) | 2011-06-20 | 2011-06-20 | Лекарственное средство для лечения патологического синдрома и способ лечения функциональных нарушений кишечника |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082245A1 true AR082245A1 (es) | 2012-11-21 |
Family
ID=44863147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102575A AR082245A1 (es) | 2010-07-15 | 2011-07-18 | Composicion farmaceutica de combinacion para tratar enfermedades funcionales o condiciones de tracto gastrointestinal |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8637030B2 (es) |
| EP (1) | EP2593138A2 (es) |
| JP (2) | JP2013532181A (es) |
| KR (1) | KR101901465B1 (es) |
| CN (1) | CN103096927A (es) |
| AR (1) | AR082245A1 (es) |
| AU (1) | AU2011278032B2 (es) |
| BR (1) | BR112013000842A2 (es) |
| CA (1) | CA2804964C (es) |
| CL (1) | CL2013000097A1 (es) |
| DE (1) | DE112011102355T5 (es) |
| EA (1) | EA030542B1 (es) |
| ES (1) | ES2425004R1 (es) |
| FR (1) | FR2962651A1 (es) |
| GB (1) | GB2496794B (es) |
| IL (1) | IL224215A (es) |
| IT (1) | ITTO20110628A1 (es) |
| MX (1) | MX2013000542A (es) |
| MY (1) | MY157564A (es) |
| NZ (1) | NZ606765A (es) |
| PE (1) | PE20130397A1 (es) |
| SG (1) | SG187035A1 (es) |
| WO (1) | WO2012007839A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| NZ606767A (en) | 2010-07-15 | 2015-08-28 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
| AU2011287288A1 (en) | 2010-07-15 | 2013-03-07 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases |
| CA2805091A1 (en) | 2010-07-15 | 2012-01-19 | Oleg Iliich Epshtein | Pharmaceutical compositions comprising a homopathically potentized form of an antibody to human cannabinoid receptor |
| GB2495885B (en) * | 2010-07-15 | 2017-11-22 | Iliich Epshtein Oleg | Combination pharmaceutical composition and methods of treating genitourinary system disorders |
| MX2013000807A (es) | 2010-07-21 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para el tratamiento del trastorno de hiperactividad con deficit de atencion. |
| DE112011102412T5 (de) | 2010-07-21 | 2013-07-04 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von mit Atemwegserkrankungen bzw. Atemwegsleiden assoziierten Erkrankungen bzw. Leiden |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| CN106349388B (zh) * | 2015-07-17 | 2021-04-02 | 上海佳文英莉生物技术有限公司 | 一种促细胞程序性坏死抗体及其应用 |
| CN207908510U (zh) | 2016-09-21 | 2018-09-25 | 维布兰特公司 | 安装在抽水马桶上的传感器 |
| WO2024111633A1 (ja) * | 2022-11-24 | 2024-05-30 | 国立大学法人徳島大学 | タンパク質に対する抗体の作製 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311897A (en) | 1979-08-28 | 1982-01-19 | Union Carbide Corporation | Plasma arc torch and nozzle assembly |
| US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| US4987127A (en) | 1989-01-31 | 1991-01-22 | Dal Sirany | Method of treating a virus outbreak |
| SU1730144A1 (ru) | 1989-02-24 | 1992-04-30 | Научный Центр По Разработке И Внедрению Современных Методов Молекулярной Диагностики | Способ подавлени репродукции вирусов |
| GB8905400D0 (en) | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
| US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| RU2007989C1 (ru) | 1991-11-12 | 1994-02-28 | Акционерное общество "Трейдис" | Способ габович подбора гомеопатических препаратов и их разовой дозы |
| US5741488A (en) | 1992-10-08 | 1998-04-21 | The Kennedy Institute For Rheumatology | Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies |
| DK140992D0 (da) | 1992-11-24 | 1992-11-24 | Ole Buchardt | Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug |
| US5879677A (en) | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
| WO1994022846A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
| RU2033784C1 (ru) | 1993-05-28 | 1995-04-30 | Индивидуальное частное предприятие "Диалог" | Устройство для репродуцирования гомеопатических и изопатических препаратов |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| EP0652014A1 (en) | 1993-11-10 | 1995-05-10 | National Institute Of Immunology | Treatment of prostatic hypertrophy |
| NZ278607A (en) | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| US5629286A (en) | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
| IL110035A0 (en) | 1994-06-16 | 1994-10-07 | Tapuach Natural Technologies 1 | Homeopathic formulations |
| RU2137483C1 (ru) | 1995-08-02 | 1999-09-20 | Божедомов Владимир Александрович | Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции |
| EA000885B1 (ru) | 1996-02-12 | 2000-06-26 | Олег Ильич ЭПШТЕЙН | Лекарственное средство и способ медикаментозного воздействия на организм |
| WO1997039772A1 (fr) | 1996-04-19 | 1997-10-30 | Chugai Seiyaku Kabushiki Kaisha | Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif |
| IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
| RU2114605C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Защитная добавка для косметических средств |
| RU2132181C1 (ru) | 1996-09-30 | 1999-06-27 | Эпштейн Олег Ильич | Средство для воздействия на организм |
| RU2114646C1 (ru) | 1996-09-30 | 1998-07-10 | Олег Ильич Эпштейн | Способ повышения защитных свойств организма при воздействии внешних физических факторов |
| RU2099052C1 (ru) | 1996-12-26 | 1997-12-20 | Тамара Михайловна Воробьева | Лекарственное средство для восстановления психофизиологического гомеостаза, нарушенного вследствие употребления алкоголя |
| RU2103999C1 (ru) | 1997-01-31 | 1998-02-10 | Олег Ильич Эпштейн | Способ лечения алкоголизма |
| RU2104006C1 (ru) | 1997-02-14 | 1998-02-10 | Олег Ильич Эпштейн | Способ лечения наркомании |
| RU2104032C1 (ru) | 1997-03-11 | 1998-02-10 | Общество с ограниченной ответственностью "Снежный барс" | Способ усиления лечебного эффекта лекарственных средств |
| DE19746868A1 (de) | 1997-10-23 | 1999-04-29 | Knoll Ag | Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen |
| RU2122858C1 (ru) | 1997-12-29 | 1998-12-10 | Яковлева Людмила Борисовна | Гомеопатическое лекарственное средство седативного действия "вернисон" |
| RU2187334C2 (ru) | 1998-05-22 | 2002-08-20 | Эпштейн Олег Ильич | Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство |
| RU2161955C1 (ru) | 1999-07-16 | 2001-01-20 | Эпштейн Олег Ильич | Способ изменения физико-химических или физико-химических и биологических свойств вещества |
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2177795C1 (ru) | 2001-02-15 | 2002-01-10 | Эпштей Олег Ильич | Гомеопатическое лекарственное средство для лечения и профилактики аденовирусных инфекций у детей |
| RU2192882C1 (ru) | 2001-04-18 | 2002-11-20 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения |
| RU2197266C1 (ru) * | 2001-06-01 | 2003-01-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта |
| WO2003037372A1 (fr) | 2001-10-31 | 2003-05-08 | Oleg Iliich Epshtein | Procede de retablissement de processus physiologiques perturbes et medicament |
| RU2201255C1 (ru) | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
| RU2001134982A (ru) | 2001-12-26 | 2004-02-20 | Олег Ильич Эпштейн | Способ коррекции иммунного ответа и лекарственное средство |
| RU2205026C1 (ru) | 2002-03-15 | 2003-05-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения |
| UA76641C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| UA76640C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| TWI345470B (en) | 2003-03-14 | 2011-07-21 | Nutrition Res Inc | Homeopathic formulations useful for treating pain and/or inflammation |
-
2011
- 2011-07-15 BR BR112013000842A patent/BR112013000842A2/pt not_active IP Right Cessation
- 2011-07-15 WO PCT/IB2011/002178 patent/WO2012007839A2/en active Application Filing
- 2011-07-15 NZ NZ606765A patent/NZ606765A/en not_active IP Right Cessation
- 2011-07-15 MX MX2013000542A patent/MX2013000542A/es active IP Right Grant
- 2011-07-15 GB GB1302654.7A patent/GB2496794B/en not_active Expired - Fee Related
- 2011-07-15 DE DE112011102355T patent/DE112011102355T5/de not_active Withdrawn
- 2011-07-15 MY MYPI2013000109A patent/MY157564A/en unknown
- 2011-07-15 SG SG2013002290A patent/SG187035A1/en unknown
- 2011-07-15 IT IT000628A patent/ITTO20110628A1/it unknown
- 2011-07-15 CA CA2804964A patent/CA2804964C/en not_active Expired - Fee Related
- 2011-07-15 US US13/135,888 patent/US8637030B2/en not_active Expired - Fee Related
- 2011-07-15 JP JP2013519174A patent/JP2013532181A/ja active Pending
- 2011-07-15 PE PE2013000075A patent/PE20130397A1/es not_active Application Discontinuation
- 2011-07-15 ES ES201390001A patent/ES2425004R1/es active Pending
- 2011-07-15 EP EP11775833.4A patent/EP2593138A2/en not_active Withdrawn
- 2011-07-15 FR FR1156469A patent/FR2962651A1/fr active Pending
- 2011-07-15 KR KR1020137003751A patent/KR101901465B1/ko active IP Right Grant
- 2011-07-15 AU AU2011278032A patent/AU2011278032B2/en not_active Ceased
- 2011-07-15 EA EA201300125A patent/EA030542B1/ru not_active IP Right Cessation
- 2011-07-15 CN CN2011800429401A patent/CN103096927A/zh active Pending
- 2011-07-18 AR ARP110102575A patent/AR082245A1/es unknown
-
2013
- 2013-01-10 CL CL2013000097A patent/CL2013000097A1/es unknown
- 2013-01-14 IL IL224215A patent/IL224215A/en active IP Right Grant
-
2016
- 2016-07-01 JP JP2016131657A patent/JP2016210787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN103096927A (zh) | 2013-05-08 |
| MY157564A (en) | 2016-06-30 |
| NZ606765A (en) | 2015-08-28 |
| EP2593138A2 (en) | 2013-05-22 |
| GB2496794A (en) | 2013-05-22 |
| EA030542B1 (ru) | 2018-08-31 |
| CL2013000097A1 (es) | 2015-01-09 |
| US20130004574A1 (en) | 2013-01-03 |
| KR20130060264A (ko) | 2013-06-07 |
| EA201300125A1 (ru) | 2013-12-30 |
| KR101901465B1 (ko) | 2018-09-21 |
| ITTO20110628A1 (it) | 2012-01-16 |
| AU2011278032A1 (en) | 2013-03-07 |
| GB201302654D0 (en) | 2013-04-03 |
| ES2425004R1 (es) | 2014-07-09 |
| SG187035A1 (en) | 2013-02-28 |
| WO2012007839A3 (en) | 2012-04-26 |
| FR2962651A1 (fr) | 2012-01-20 |
| JP2016210787A (ja) | 2016-12-15 |
| AU2011278032B2 (en) | 2015-07-23 |
| MX2013000542A (es) | 2013-06-28 |
| ES2425004A2 (es) | 2013-10-10 |
| DE112011102355T5 (de) | 2013-04-25 |
| CA2804964C (en) | 2016-06-28 |
| IL224215A (en) | 2016-03-31 |
| WO2012007839A2 (en) | 2012-01-19 |
| CA2804964A1 (en) | 2012-01-19 |
| BR112013000842A2 (pt) | 2016-06-07 |
| PE20130397A1 (es) | 2013-04-10 |
| JP2013532181A (ja) | 2013-08-15 |
| US8637030B2 (en) | 2014-01-28 |
| GB2496794B (en) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082245A1 (es) | Composicion farmaceutica de combinacion para tratar enfermedades funcionales o condiciones de tracto gastrointestinal | |
| AR082313A1 (es) | Composicion farmaceutica de combinacion para tratar enfermedades o condiciones asociadas una enfermedad o condicion respiratoria | |
| BR112018074155A2 (pt) | anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo | |
| EA201190018A1 (ru) | Миостатинсвязывающие белки | |
| AR059922A1 (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos | |
| UY31466A1 (es) | Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden | |
| EA201171285A1 (ru) | Новая технология изготовления диклофенака | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| EA201171286A1 (ru) | Новая технология изготовления индометацина | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| PA8849001A1 (es) | Anticuerpos de c-met | |
| BR112012019098A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| EA201270813A1 (ru) | АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ | |
| EA201171284A1 (ru) | Новая технология изготовления напроксена | |
| RU2011142183A (ru) | Средство для лечения ревматоидного артрита | |
| EA201491452A1 (ru) | Антитела к asic1 и их применение | |
| EA201591618A1 (ru) | Замещенные имидазопиридазины | |
| JP2013535445A5 (es) | ||
| JP2013533269A5 (es) | ||
| EA201591133A1 (ru) | СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19 | |
| PE20141683A1 (es) | Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs) | |
| AR080432A1 (es) | Proteinas de union a antigeno | |
| JP2013538186A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |